First - despite what you'll hear - it is pirTobrutinib, not pirobrutinib.

Second - lots of great information on the current state of targeted therapies in adjuvant NSCLC and on two exciting new drugs: elacestrant and pirtobrutinib.

First - despite what you'll hear - it is pirTobrutinib, not pirobrutinib. Second - lots of great information on the current state of targeted therapies in adjuvant NSCLC and on two exciting new drugs: elacestrant and pirtobrutinib.

Adjuvant Pembrolizumab (NSCLC), Elacestrant, & Pirtobrutinib

OncoPharm is a podcast dedicated to all things oncology pharmacy.  Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer.  Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.

Science

OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.

Share Adjuvant Pembrolizumab (NSCLC), Elacestrant, & Pirtobrutinib

Sign up to save your podcasts

Adjuvant Pembrolizumab (NSCLC), Elacestrant, & Pirtobrutinib

Adjuvant Pembrolizumab (NSCLC), Elacestrant, & Pirtobrutinib

More shows like OncoPharm

JAMA Clinical Reviews

The Daily

Up First from NPR

Armchair Expert with Dax Shepard

ASCO Guidelines

The Peter Attia Drive

OncLive® On Air

Raising Good Humans

Oncology Today with Dr Neil Love

Huberman Lab

The Money with Katie Show

Two Onc Docs

Oncology Brothers: Practice-Changing Cancer Discussions

WolverHeme Happy Hour

Good Hang with Amy Poehler